<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905967</url>
  </required_header>
  <id_info>
    <org_study_id>20190031</org_study_id>
    <nct_id>NCT03905967</nct_id>
  </id_info>
  <brief_title>TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC</brief_title>
  <acronym>TACE</acronym>
  <official_title>Transarterial Chemoembolization With Lenvatinib Versus Lenvatinib Alone in First-line Treatment of Advanced Hepatocellular Carcinoma: a Phase III, Multicenter, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is is an open label, multicenter, randomized controlled phase 3 clinical trial.
      The purpose is to compare the efficacy and safety of lenvatinib plus TACE with lenvatinib
      alone for advanced HCC patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>two years</time_frame>
    <description>Defined as the time from randomization to death for any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>two years</time_frame>
    <description>Defined as the time from randomization to disease progression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Lenvatinib + TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Lenvatinib + TACE group will take oral lenvatinib within 3 days of randomization and receive TACE 1 day after oral administration of lenvatinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenvatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lenvatinib alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE will be performed one day after oral administration of lenvatinib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of each center.</description>
    <arm_group_label>Lenvatinib + TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients &lt;60kg, and 12 mg qd for patients &gt;60kg)</description>
    <arm_group_label>Lenvatinib</arm_group_label>
    <arm_group_label>Lenvatinib + TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 years old;

          2. Patients with primary advanced HCC (in accordance with AASLD2018 guidelines for the
             diagnosis of HCC), without any previous treatment;

          3. There is at least one measurable lesion in the liver according to mRECIST criteria,
             single tumor ≤ 10.0 cm or multiple tumors and tumor burden ≤50% , with portal vein
             tumor embolus or with extrahepatic metastasis;

          4. ECOG score 0-1;

          5. Child-Pugh class A;

          6. Expected survival time ≥ 3 months;

          7. Blood, liver and kidney function meet the following conditions: Neutrophil count ≥ 1.5
             × 10 9 /L; Platelet count ≥ 60 × 10 9 /L; Hemoglobin ≥ 90 g/L; Serum albumin ≥ 30 g/L;
             Bilirubin ≤ 50 umol/L; AST, ALT ≤ 5 times the upper limit of normal, ALP ≤ 4 times the
             upper limit of normal; Prolongation of prothrombin time not to exceed the upper limit
             of normal by 6 seconds; Creatinine ≤ 1.5 times the upper limit of normal

        Exclusion Criteria:

          1. Preoperative imaging examination revealed diffuse intrahepatic lesions or invasion,
             inferior vena cava or primary branch bile duct;

          2. Previous history of hepatic encephalopathy, refractory ascites or gastric esophageal
             varices;

          3. There are contraindications to TACE treatment, such as portosystemic shunt, liver flow
             ablation, significant atherosclerosis;

          4. Brain metastases;

          5. Hypersensitivity to intravenous contrast agents;

          6. Pregnant or lactating women or subjects with family planning within two years;

          7. With HIV, syphilis infection;

          8. Accompanied by other malignant tumors or suffering from other malignancies within 5
             years before enrollment;

          9. Allogeneic organ transplant recipients;

         10. Severe dysfunction of heart and kidney or other organs;

         11. Active severe infection &gt; grade 2 (NCI-CTC version 4);

         12. Suffering from mental and psychological diseases may affect informed consent;

         13. Unable to take oral medication;

         14. Participated in other drug clinical trials within 12 months before enrollment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Kuang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Kuang, PhD</last_name>
    <phone>008687755766</phone>
    <email>kuangm@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Kuang, Ph.D.</last_name>
      <phone>008687755766</phone>
      <phone_ext>8576</phone_ext>
      <email>kuangm@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.</citation>
    <PMID>29433850</PMID>
  </reference>
  <reference>
    <citation>Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5. Review.</citation>
    <PMID>29307467</PMID>
  </reference>
  <reference>
    <citation>Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23. Erratum in: Lancet Gastroenterol Hepatol. 2017 Sep;2(9):e6.</citation>
    <PMID>28648803</PMID>
  </reference>
  <reference>
    <citation>Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol. 2019 Apr;70(4):684-691. doi: 10.1016/j.jhep.2018.11.029. Epub 2018 Dec 6.</citation>
    <PMID>30529387</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming Kuang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Lenvatinib</keyword>
  <keyword>Transarterial chemoembolisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

